This single-arm, multicenter clinical study enrolled patients with advanced malignant melanoma who had failed previous first-line therapy (cutaneous melanoma patients were excluded), and patients with BRAF V600 mutations required targeted therapy.
Have fully understood the study and voluntarily signed the informed consent;
Age 18-75 years old (including 18 and 75 years old), gender is not limited;
Stage IV melanoma determined by pathology or cytology;
Patients with advanced malignant melanoma who have failed previous first-line therapy (cutaneous melanoma patients are excluded) and patients with BRAF V600 mutations need to be admitted after targeted therapy.
Failure to comply with the study protocol or study procedure;
Patients with active brain metastases;
Received organ surgery 6 weeks before enrollment;
Had other malignant tumors within 5 years prior to admission, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;